Trials / Completed
CompletedNCT01849562
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
A Phase 2a Trial to Evaluate the Safety, Tolerability, and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV) participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sovaprevir | Nonstructural protein 3/4A protease inhibitor. |
| DRUG | ACH-3102 | Nonstructural protein 5A inhibitor. |
| DRUG | Ribavirin | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2013-11-01
- Completion
- 2014-04-01
- First posted
- 2013-05-08
- Last updated
- 2023-08-29
- Results posted
- 2015-02-04
Source: ClinicalTrials.gov record NCT01849562. Inclusion in this directory is not an endorsement.